Ackrell Capital Cannabis Investment Report (Dec 2017) – Canadian Stock Market Comparison
Summary
The document is a routine market analysis with no mention of high‑profile individuals, government agencies, or controversial transactions. It provides generic data on exchange listings and financial c Shows that >10% of Canadian Securities Exchange listings are cannabis‑related. Compares market size and median company values across TSX, TSXV, and CSE. Outlines listing and governance requirements f
This document is from the House Oversight Committee Releases.
View Source CollectionPersons Referenced (3)
Tags
Related Documents (6)
Cannabis Investment Report – Market Overview and Funding Landscape (Dec 2017)
The document is a generic industry analysis with no mention of high‑profile political figures, intelligence agencies, or controversial financial flows. It provides market commentary and fundraising to Reports $2.0 billion raised by cannabis‑related companies in 2017. Highlights Canadian exchanges (TSX, TSXV, CSE) as primary venues for cannabis listings. Notes ongoing U.S. federal prohibition limit
Cannabis Industry Segments Report – Production Overview (Dec 2017)
The passage is a generic industry overview of cannabis production, containing no references to high‑profile individuals, government agencies, financial misconduct, or controversial actions. It offers Divides cannabis production into cultivation, equipment/supplies, and testing services. Describes cultivation phases and inputs. Published by Ackrell Capital, LLC, a FINRA‑registered firm.
Ackrell Capital Cannabis OTC Market Valuation Table (2017)
The document is a financial listing of small OTC cannabis companies with market metrics. It contains no references to influential political figures, government agencies, or alleged misconduct, offerin Provides EV multiples and stock price discounts for over 40 cannabis firms. Compiled by Ackrell Capital, a FINRA/SIPC member. Data dated November 30, 2017.
Synthetic biology and QA/QC testing market for cannabinoids
The passage is a commercial market analysis describing production methods and testing opportunities for CBD. It mentions no high‑profile officials, agencies, or controversial financial flows, and prov Synthetic biology can produce cannabinoids via fermentation. QA/QC testing standards for CBD are currently fragmented across states. Life‑science instrument makers (Agilent, Danaher, PerkinElmer, Shi
Overview of Federal and State Cannabis Regulations and Emerging Policy Shifts
The passage provides a general summary of cannabis regulatory frameworks and mentions recent policy changes (DEA 2016 cultivator expansion, FDA NDA review) but offers no concrete leads, names, transac State governments are adjusting recreational cannabis regulations. Federal law still prohibits cannabis but DOJ and Treasury policies create limited operational space. DEA adopted a 2016 policy to in
Cannabis Company Valuation Table from Cowen Report (Feb 2019)
The passage is a plain financial data table listing market metrics for cannabis companies. It contains no references to high‑profile individuals, government actions, or alleged misconduct, offering no Provides enterprise values, revenues, and price metrics for dozens of cannabis firms. Cites Thomson Reuters and Cowen as sources. Dated February 25, 2019, with no contextual commentary.
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.